Jun. 9 at 5:40 PM
$ZNTL Let’s talk about ZNTL.
I'm curious what others think here and what I might be missing.
At roughly
$3.50/share, Zentalis is trading only modestly above cash on hand. Meanwhile, azenosertib is advancing through the final stages of DENALI 2B, which appears to have a credible path toward accelerated approval in platinum-resistant ovarian cancer (PROC).
The recent addition of DENALI Part 2C, which evaluates patients with prior taxane exposure, seems particularly important. It further addresses the unmet medical need argument and may strengthen the overall accelerated approval package.
We've already seen objective response rates (ORRs) in the 30% range in the Cyclin E1-positive population, with median duration of response (mDOR) around six months. The company has also moved the study into patients with fewer prior lines of therapy. Historically, when therapies move earlier in the treatment paradigm, response rates often improve— substantially - a 10% ORR increase would not be unheard of.
